BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter regarding Relistor®: Occurrence of gastrointestinal perforations

2010.09.13

Active substance: methylnaltrexone bromide

Important safety information on the occurrence of gastrointestinal perforations in patients who received RELISTOR® (active substance: methylnaltrexone bromide) for subcutaneous injection.
An Rote-Hand-Brief including the

Fachinformation PDF, 112KB, File is accessible

will be circulated.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 2MB, File is accessible